Tekla Capital Management’s Mereo BioPharma MREO Stock Holding History

Tekla Capital Management’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$2.05M	Hold	1,551,082	–	–	0.08%	112
2023 Q1	$1.1M	Hold	1,551,082	–	–	0.04%	137
2022 Q4	$1.16M	Hold	1,551,082	–	–	0.04%	132
2022 Q3	$1.34M	Hold	1,551,082	–	–	0.05%	124
2022 Q2	$1.74M	Hold	1,551,082	–	–	0.07%	117
2022 Q1	$1.74M	Hold	1,551,082	–	–	0.06%	130
2021 Q4	$2.48M	Hold	1,551,082	–	–	0.08%	123
2021 Q3	$3.75M	Buy	1,551,082 +506,292	+48%	+$1.34M	0.12%	115
2021 Q2	$3.31M	Buy	1,044,790 +47,500	+5%	+$159K	0.11%	137
2021 Q1	$3.36M	Buy	+997,290	New	+$3.53M	0.12%	139

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Tekla Capital Management's MREO Position: Q2 2023 in Review

Tekla Capital Management held its Mereo BioPharma (MREO) position steady in Q2 2023 at 1,551,082 shares worth $2.05M. The position accounts for 0.08% of the portfolio, ranked #112.

Tekla Capital Management first reported a position in MREO in Q1 2021 and has held it in 10 quarters since. The position peaked at $3.75M in Q3 2021. 53 funds tracked by Wall St. Rank hold MREO as of Q2 2023.

Tekla Capital Management held 1,551,082 shares of Mereo BioPharma worth $2.05M as of Q2 2023.
Tekla Capital Management left its Mereo BioPharma share count unchanged in Q2 2023.
Mereo BioPharma made up 0.08% of Tekla Capital Management's portfolio in Q2 2023, its #112 holding.
Tekla Capital Management first reported a position in Mereo BioPharma in Q1 2021 and has held it in 10 quarters since.
Tekla Capital Management's Mereo BioPharma position peaked at $3.75M in Q3 2021.
53 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.